Baidu
map

J Dairy Sci:乳制品中的特殊蛋白或可保护机体抵御心血管疾病

2015-06-16 佚名 生物谷

美拉德反应是一种在复杂糖和氨基酸之间发生的褐变反应,当蛋白质和糖类混合在一起被加热时就会产生新的化合物,有些就会产生新的香料及其它物质,近日一篇发表在国家杂志Journal of Dairy Science上的研究论文中,来自高丽大学等处的研究人员就发现牛奶中的蛋白质可以帮助机体抵御心血管疾病的发生。 文章中研究者表示,一种在乳制品中形成的饮食化合物可以降低小鼠机体血清中总的胆固醇水平、低密度脂

美拉德反应是一种在复杂糖和氨基酸之间发生的褐变反应,当蛋白质和糖类混合在一起被加热时就会产生新的化合物,有些就会产生新的香料及其它物质,近日一篇发表在国家杂志Journal of Dairy Science上的研究论文中,来自高丽大学等处的研究人员就发现牛奶中的蛋白质可以帮助机体抵御心血管疾病的发生。

文章中研究者表示,一种在乳制品中形成的饮食化合物可以降低小鼠机体血清中总的胆固醇水平、低密度脂蛋白(LDL)胆固醇的水平以及甘油三酯的水平,同时这些化合物也会像阿司匹林一样保护机体抵御急性肺血栓栓塞症,但并不会出现像阿司匹林疗法一样产生可能性的出血事件。

乳清蛋白浓缩物和酪蛋白酸钠同乳糖一起进行加热后就会产生乳清蛋白美拉德反应产物,随后乳酸菌就会利用其制造已经发酵的美拉德产物,而酪蛋白酸钠也会发生反应形成美拉德反应酪蛋白酸钠以及已经发酵的美拉德反应酪蛋白酸钠产物。

为了确定抗血栓药物的效果,研究者将60只小鼠分为四个治疗组,每组15只小鼠,第一组小鼠接受PBS,作为阴性对照组,第二组接受阿司匹林,作为阳性对照组,第三组接受乳清蛋白美拉德反应产物,第四组接受将发酵的美拉德产物同正常饮食进行搭配进行研究。同时研究者利用添加或不添加发酵的美拉德反应酪蛋白酸钠产物的多种饮食来对另外60只小鼠进行研究,来评估美拉德反应酪蛋白酸钠的抗氧化活性及降胆固醇效应。

结果研究者发现,美拉德反应产物及其发酵产物都可以降低动物模型的心血管疾病发病风险,另外研究者还指出,美拉德反应酪蛋白酸钠及其发酵产物应当被推荐作为抗氧化剂及保护心脏的制剂用于多种制药、功能性以及乳酪行业。本文研究或可帮助研究者理解乳制品对人类机体健康的额外价值,目前该研究仅在实验室对动物模型进行了研究,后期研究人员将对人类进行研究评估乳制品的产物对人类心血管健康的正向作用。

原始出处

N.S. Oh*, M.R. Park†, K.W. Lee†, S.H. Kim†, 1, , Y. Kim‡.et.al.Dietary Maillard reaction products and their fermented products reduce cardiovascular risk in an animal model .J Dairy Sci.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-29 owlhealth

    好的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-21 caierhong

    很多国家的模式值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-21 caierhong

    安全是个大问题

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-21 caierhong

    监管部门不到位

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-16 summer474cn

    中国的可以吗?

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=29875, encodeId=8442298e51c, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29276, encodeId=79bf292e6b3, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:18:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28605, encodeId=64b228605dc, content=很多国家的模式值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:27:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28603, encodeId=14f428603a3, content=安全是个大问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28604, encodeId=a37228604e1, content=监管部门不到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66c61628089, createdName=caierhong, createdTime=Sun Jun 21 21:26:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497889, encodeId=acf9149e88979, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Jun 18 08:32:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27813, encodeId=da162e81309, content=中国的可以吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27814, encodeId=e5fd2e814ea, content=中国食品药品安全问题存在隐患, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 16 18:05:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
    2015-06-16 summer474cn

    中国食品药品安全问题存在隐患

    0

相关资讯

TECOS心血管安全性研究达到主要终点

(2015年6月8日,美国新泽西)默沙东公司(在美国与加拿大称为默克)宣布了"评估2型糖尿病口服药物西格列汀心血管安全性的临床研究"(TECOS)的结果。相关数据已在线发表于最新一期《新英格兰医学杂志》,并在第75届美国糖尿病学会年会上同步揭晓。 TECOS是一项随机,双盲,安慰剂对照试验,由默沙东申办,牛津大学糖尿病试验团队和杜克大学临床研究中心牵头实施。患者入组始于2008年,直至2012年

ADA 2015:DPP-4抑制剂西格列汀心血管安全性良好(TECOS研究)

TECOS研究是一项有关伴心血管疾病的2型糖尿病患者在接受常规治疗基础上,加用二肽基肽酶-4(DPP-4)抑制剂西格列汀对此类患者心血管事件影响的随机、双盲、安慰剂对照试验。其结果显示,西格列汀不增加此类患者达到心血管死亡、非致死性心梗、非致死性卒中或不稳定心绞痛住院的复合终点事件风险,也不增加心衰住院或其他不良反应事件的风险。该研究共计纳入14671例患者,在其现有治疗基础上被随机分为加用西格列

JAMIA:出生月份原来真的可以影响一个人的健康

出生月份可显著影响个体一生所患的疾病,先前的研究表明出生月份与许多疾病,包括动脉粥样硬化、哮喘、多动症以及近视有关,此外尚有许多疾病并未明确与出生月份之间的关系。本次回顾性研究的目的是为了探讨季节对个体出生和一生所患疾病的影响。

J Dent Res:从缺失牙齿预测心血管疾病,糖尿病以及死亡

J Dent Res:从缺失牙齿预测心血管疾病,糖尿病以及死亡的发生 牙周炎,是中老年人牙齿丧失的主要原因,同时也是动脉粥样硬化性心血管疾病的危险因素。本研究的目的是为了探究牙齿丧失的数目是否可预测心血管疾病(CVDs),糖尿病以及死亡的发生。国家 FINRISK1997研究是基于8446名人群的调查研究以及13年的随访研究。基线时期记录研究对象的牙齿状况,并通过国家登记册获得人群CVD

ADA 2015:阿格列汀未增加ACS患者心血管事件(EXAMINE试验)

EXAMINE试验中有关心肌缺血事件和心血管住院率的所有数据以口头报告的形式公布。EXAMINE试验评估了近期发生急性冠脉综合征的2型糖尿病患者在接受DPP-4抑制剂阿格列汀后的心血管事件。结果显示,在EXAMINE试验人群中,心肌梗死及不稳定型心绞痛、冠脉重建、心血管事件住院以及这些缺血性事件构成的复合终点的发生率普遍较高,尤其是心血管事件住院率及冠脉重建。但以上心肌缺血事件在阿格列汀组和安慰剂

J Dental Res:掉了几颗牙?看你健康不

牙齿提前脱落通常表明一个人口腔疾病的历史。芬兰赫尔辛基大学与国家卫生福利研究院的研究人员在广泛的队列研究结果后,发现牙齿提前脱落与未来心血管事件,糖尿病和死亡有关。缺牙的数目可能作为医生评估慢性疾病风险因素时的一个有用的附加指标。这篇文章发表在Journal of Dental Research。 The National FINRISK 1997研究是以芬兰人口为基础的调查。对8446位年龄在

Baidu
map
Baidu
map
Baidu
map